15 Analysts Assess Axsome Therapeutics: What You Need To Know
Portfolio Pulse from Benzinga Insights
15 analysts have recently evaluated Axsome Therapeutics (NASDAQ:AXSM), with a mix of bullish and somewhat bullish ratings. The average 12-month price target has increased by 7.07% to $137.8. Analysts have adjusted their ratings and price targets, reflecting their responses to recent developments. Despite positive analyst sentiment, Axsome faces financial challenges, including a decline in revenue, low net margin, and high debt-to-equity ratio.
June 05, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Axsome Therapeutics has received mostly bullish ratings from analysts, with an average 12-month price target increase of 7.07% to $137.8. However, the company faces financial challenges, including a decline in revenue, low net margin, and high debt-to-equity ratio.
The majority of analysts have a positive outlook on Axsome Therapeutics, reflected in the increased average price target. However, the company's financial challenges, such as declining revenue and high debt, may temper the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100